Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
RYGB (roux-en-y gastric bypass) has been reported to reverse type 2 diabetes (T2DM)
immediately after surgery before any significant weight loss. In addition, a growing number
of patients have been recognized with life-threatening hyperinsulinemic hypoglycemia several
years following their surgery. While the mechanisms by which RYGB improves glucose metabolism
or alters islet cell function in patients after RYGB are not understood, recent studies
suggest that increased secretion of GI hormones, primarily glucagon-like peptide 1 (GLP-1),
as well as alteration in neural activity may contribute to enhanced insulin secretion in
general, and to a greater extent in patients with hypoglycemia. The proposed research is
designed to address the role of RYGB on insulin secretion by evaluating the contribution of
stimulatory factors (neural and GI hormone) on islet cell function and the islet cell
responsiveness to the physiologic stimulatory factors, in RYGB patients with and without
hypoglycemia and non-operated controls.
Phase:
Early Phase 1
Details
Lead Sponsor:
Cedars-Sinai Medical Center The University of Texas Health Science Center at San Antonio